TP53 in Cancer Overview

This section brings together TP53 testing, interpretation, variant and mutation types, treatment-planning implications, and practical support ideas.

It is organised around the key distinctions that matter most in practice: germline versus somatic findings, common SNP-level variation versus pathogenic mutations, and mutation type rather than gene name alone.

Start here

If you are new to this topic, follow this order:

1. Why Test Type Matters

2. TP53 SNPs and Nutrigenomics

3. Germline TP53

4. Somatic TP53

5. TP53 Mutation Types Reference

That sequence gives the clearest learning flow.

It starts with the common test-type issue, then moves from common lower-impact variation into inherited high-impact findings, then into tumour-acquired mutations.

Core interpretation pages

• Why Test Type Matters
  Why a TP53 result means very little until you know whether it came from a nutrigenomic report, a hereditary panel, or a tumour test.

• TP53 SNPs and Nutrigenomics
  Common TP53 variation, rs1042522, and the wider DNA-repair context that is most actionable through diet, nutrients, and exposure reduction.

• Germline TP53
  Inherited TP53 findings, Li-Fraumeni-spectrum implications, treatment-planning relevance, and why this question can matter before radiotherapy or genotoxic chemotherapy.

• Somatic TP53
  Tumour-acquired TP53 mutations, report interpretation, tissue versus liquid biopsy, and what the tumour is actually doing now.

  • TP53 Mutation Types Reference
    Practical decoder for hotspot missense mutations, partial-loss variants, frameshift and nonsense mutations, splice variants, and null states.

Tests ordered and received, now what?

• Food and Lifestyle Support
  Realistic support around DNA repair, inflammation, oxidative load, and micronutrients without overclaiming what lifestyle can do.

• Questions for Oncologists
  Practical questions to bring into the clinic when results are discussed, so the test type, mutation class, and treatment implications actually get discussed.

Strategy-related pages

• Fenbendazole and TP53
  Why tumour wild-type versus mutant or null p53 can change how favourable the fenbendazole biology looks.

• Mebendazole and TP53
  Why mebendazole appears less dependent on intact p53 than fenbendazole, while still engaging p53 pathways in some models.

• Andrographis and Mutant p53
  Educational overview of the mutant-p53 clean-up pulse idea, including the Hsp70-proteasome rationale and the main safety cautions.

• NAC in p53-Mutant Cancers
  Why NAC may raise more concern in stable gain-of-function mutant-protein states than in p53-null settings.

How to use this section

Use this hub in one of three ways:

1. To decode a report
   Start with test type, then find the mutation class.

2. To understand treatment implications
   Focus on the germline versus somatic split first.

3. To explore support ideas more carefully
   Read the mutation pages before the strategy pages, so the biology stays matched to the intervention.